Literature DB >> 3409646

Joint hypermobility in primary mitral valve prolapse patients.

M Ondrasík1, I Rybár, V Rus, V Bosák.   

Abstract

Twenty-seven patients with echocardiographic evidence of primary mitral valve prolapse (MVP) were tested for the presence of joint hypermobility using the criteria of Beighton and Horan. In the examined group, joint hypermobility was found in 14 patients (52%). This occurrence was statistically significant. In patients with simultaneous occurrence of MVP and articular hypermobility we have found a number of pathologic arthrologic manifestations, such as arthralgias, synovitic reactions, distortions, low back pain, and others. In patients with articular hypermobility, there were increased functions of antigen B 35.

Entities:  

Mesh:

Year:  1988        PMID: 3409646     DOI: 10.1007/bf02284059

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  10 in total

1.  [Study of the HLA system in the Slovak population. Incidence of Antigens of the A, B, and C locus (author's transl)].

Authors:  S Nyulassy; V Hirschová; M Buc; E Silvánová; J Stefanovic
Journal:  Bratisl Lek Listy       Date:  1977-10       Impact factor: 1.278

2.  Orthopaedic aspects of the Ehlers-Danlos syndrome.

Authors:  P Beighton; F Horan
Journal:  J Bone Joint Surg Br       Date:  1969-08

3.  Accumulation of procollagen in human floppy mitral valves.

Authors:  D Bonella; D J Parker; M J Davies
Journal:  Lancet       Date:  1980-04-19       Impact factor: 79.321

4.  [Mitral valve prolapse].

Authors:  G I Storozhakov
Journal:  Vopr Revm       Date:  1982 Apr-Jun

5.  Prevalence of clinical mitral-valve prolapse in 1169 young women.

Authors:  P M Procacci; S V Savran; S L Schreiter; A L Bryson
Journal:  N Engl J Med       Date:  1976-05-13       Impact factor: 91.245

6.  The hypermobility syndrome. Musculoskeletal complaints associated with generalized joint hypermobility.

Authors:  J A Kirk; B M Ansell; E G Bywaters
Journal:  Ann Rheum Dis       Date:  1967-09       Impact factor: 19.103

7.  The floppy mitral valve. Study on pathogenesis.

Authors:  E G Olsen; H K Al-Rufaie
Journal:  Br Heart J       Date:  1980-12

8.  Mitral valve prolapse and joint hypermobility: evidence for a systemic connective tissue abnormality?

Authors:  D Pitcher; R Grahame
Journal:  Ann Rheum Dis       Date:  1982-08       Impact factor: 19.103

9.  A clinical and echocardiographic study of patients with the hypermobility syndrome.

Authors:  R Grahame; J C Edwards; D Pitcher; A Gabell; W Harvey
Journal:  Ann Rheum Dis       Date:  1981-12       Impact factor: 19.103

10.  Inheritance of mitral valve prolapse: effect of age and sex on gene expression.

Authors:  R B Devereux; W T Brown; R Kramer-Fox; I Sachs
Journal:  Ann Intern Med       Date:  1982-12       Impact factor: 25.391

  10 in total
  6 in total

1.  Intrarater and Interrater Reliability of the Beighton and Horan Joint Mobility Index.

Authors:  Kyndall L. Boyle; Philip Witt; Cheryl Riegger-Krugh
Journal:  J Athl Train       Date:  2003-12       Impact factor: 2.860

Review 2.  'The hypermobility syndrome'.

Authors:  R Grahame
Journal:  Ann Rheum Dis       Date:  1990-03       Impact factor: 19.103

3.  Adult women with mitral valve prolapse are more flexible.

Authors:  C G S Araújo; C P G Chaves
Journal:  Br J Sports Med       Date:  2005-10       Impact factor: 13.800

4.  Joint hypermobility in adults referred to rheumatology clinics.

Authors:  A J Bridges; E Smith; J Reid
Journal:  Ann Rheum Dis       Date:  1992-06       Impact factor: 19.103

5.  Joint hypermobility in children with idiopathic scoliosis: SOSORT award 2011 winner.

Authors:  Dariusz Czaprowski; Tomasz Kotwicki; Paulina Pawłowska; Lukasz Stoliński
Journal:  Scoliosis       Date:  2011-10-07

6.  The mitral valve prolapse frequency in healthy females with generalized joint hypermobility: A case-control study.

Authors:  Hande Özdemir; Filiz Tuna; Meryem Aktoz; Nurettin Taştekin; Derya Demirbağ Kabayel
Journal:  Arch Rheumatol       Date:  2021-01-21       Impact factor: 1.472

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.